source
- Rezdiffra Beats Wall Street Forecasts as MASH Market ExpandsRezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…
- Astellas revisits gene therapy for XLMTM, offering new hope after earlier setbacksA gene therapy for the rare muscle disorder X‑linked myotubular myopathy (XLMTM) showed mixed results in early trials, with some boys experiencing dramatic recoveries while others died. Astellas P…